RecruitingPhase 2NCT05563467

Pembrolizumab in the Treatment of Advanced, Progressive Adrenocortical Carcinoma.

Studying Adrenocortical carcinoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Maria Sklodowska-Curie National Research Institute of Oncology
Intervention
Pembrolizumab 25 MG/ML [Keytruda](drug)
Enrollment
24 enrolled
Eligibility
18 years · All sexes
Timeline
20232027

Study locations (4)

Collaborators

Biostat Sp. z o.o.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05563467 on ClinicalTrials.gov

Other trials for Adrenocortical carcinoma

Additional recruiting or active studies for the same condition.

See all trials for Adrenocortical carcinoma

← Back to all trials